The Ivy Brain Tumor Center at Barrow Neurological Institute announced the treatment of their first patient in a Phase 0 clinical trial for newly diagnosed glioblastoma and recurrent glioblastoma. This trial is investigating Pamiparib’s effect on crossing the blood brain barrier during treatment. Pamiparib is an investigational small molecule PARP inhibitor and PARP is a protein that plays an important role in cell survival response to DNA damage.

“This trial is significant, both because it is open to newly diagnosed glioblastoma (nGBM) patients and because it is a chance to better understand pamiparib’s ability to cross the blood-brain barrier.”

Yong (Ben) Ben, M.D., Chief Medical Officer, Immuno-Oncology at BeiGene.

Learn more about Ivy Brain Tumor Center and their Phase 0 clinical trial here.